Fu DJ, Keenan TD, Faes L, et al. - Researchers conducted this retrospective cohort study for exploring the potential usefulness of survival analysis techniques for retrospective clinical practice visual outcomes. Between October 28, 2008, and February 1, 2020, 7,802 eyes out of 10,744 eyes with neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor (VEGF) therapy met study criteria. According to findings, patients with neovascular age-related macular degeneration starting anti-VEGF therapy were more likely to receive good visual effects in the first 2.0 years after treatment, usually maintaining this outcome for 1.1 years but then worsening to poor vision within 8.7 years. Such results show the potential usefulness of the proposed analyses. In combination with the statistical approach for retrospective analysis, this data set may provide long-term prognostic information for newly diagnosed patients with this condition.